anmelden
OMX Copenhagen 20
1.544,40
PKT
+5,93
PKT
+0,39
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu OMX Copenhagen 20-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 06.08.20 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 06.08.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 20.07.20 | Novo Nordisk Neutral | UBS AG | |
| 16.07.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 16.07.20 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 06.07.20 | A.P. Moeller - Maersk A-S (B) buy | Deutsche Bank AG | |
| 02.07.20 | A.P. Moeller - Maersk A-S (B) Underweight | Barclays Capital | |
| 22.06.20 | Novo Nordisk Neutral | Oddo BHF | |
| 19.06.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 19.06.20 | A.P. Moeller - Maersk A-S (B) neutral | Jefferies & Company Inc. | |
| 17.06.20 | A.P. Moeller - Maersk A-S (B) Neutral | Goldman Sachs Group Inc. | |
| 17.06.20 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 16.06.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 15.06.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 12.06.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 12.06.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 11.06.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 05.06.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 05.06.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 05.06.20 | Novo Nordisk Neutral | UBS AG | |
| 01.06.20 | A.P. Moeller - Maersk A-S (B) overweight | JP Morgan Chase & Co. | |
| 29.05.20 | A.P. Moeller - Maersk A-S (B) Underweight | Barclays Capital | |
| 28.05.20 | A.P. Moeller - Maersk A-S (B) Sell | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 26.05.20 | A.P. Moeller - Maersk A-S (B) Hold | Jefferies & Company Inc. | |
| 21.05.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 14.05.20 | Novo Nordisk Neutral | UBS AG | |
| 14.05.20 | A.P. Moeller - Maersk A-S (B) buy | HSBC | |
| 14.05.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 13.05.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 13.05.20 | A.P. Moeller - Maersk A-S (B) buy | Jefferies & Company Inc. | |
| 13.05.20 | A.P. Moeller - Maersk A-S (B) neutral | Goldman Sachs Group Inc. | |
| 13.05.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 12.05.20 | A.P. Moeller - Maersk A-S (B) buy | HSBC | |
| 12.05.20 | A.P. Moeller - Maersk A-S (B) Hold | Kepler Cheuvreux | |
| 11.05.20 | Novo Nordisk Neutral | UBS AG | |
| 07.05.20 | Novo Nordisk overweight | Barclays Capital | |
| 07.05.20 | Novo Nordisk Outperform | Credit Suisse Group | |
| 06.05.20 | Novo Nordisk buy | UBS AG | |
| 06.05.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 06.05.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. |